A61K 41/0038
Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
Official title: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
A61K41/0038 (Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy) appears on 473 US grants and 719 published applications in this corpus.
Search patents in A61K- Granted patents
- 473
- Published applications
- 719
- Assignees
- 411
- Inventors
- 1,291
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 8 | 0 |
| 1996 | 12 | 0 |
| 1997 | 15 | 0 |
| 1998 | 14 | 0 |
| 1999 | 11 | 0 |
| 2000 | 8 | 0 |
| 2001 | 10 | 5 |
| 2002 | 8 | 28 |
| 2003 | 16 | 42 |
| 2004 | 12 | 33 |
| 2005 | 16 | 21 |
| 2006 | 10 | 24 |
| 2007 | 5 | 14 |
| 2008 | 10 | 21 |
| 2009 | 7 | 11 |
| 2010 | 6 | 20 |
| 2011 | 11 | 30 |
| 2012 | 15 | 32 |
| 2013 | 13 | 27 |
| 2014 | 15 | 24 |
| 2015 | 17 | 33 |
| 2016 | 18 | 31 |
| 2017 | 21 | 39 |
| 2018 | 18 | 41 |
| 2019 | 33 | 32 |
| 2020 | 26 | 38 |
| 2021 | 22 | 26 |
| 2022 | 24 | 35 |
| 2023 | 13 | 43 |
| 2024 | 18 | 26 |
| 2025 | 11 | 24 |
| 2026 | 16 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating cancer using x-ray-induced near infrared photoimmunotherapy8 Sep 2026US 12,728,164 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer16 Jun 2026US 12,653,890 B2Nanobiotix
- Therapy19 May 2026US 12,629,382 B2Vestlandets Innovasjonsselskap AS
- Radiation sensitizer of anti-cancer chemotherapy sensitizer5 May 2026US 12,616,650 B2
- Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof21 Apr 2026US 12,605,472 B2Actinium Pharmaceuticals, Inc.
- Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer1 Oct 2026US 2026/0295047 A1Nanobiotix
- Radiation sensitivity enhancing composition containing aripiprazole as active ingredient17 Sep 2026US 2026/0272916 A1Korea Institute of Radiological & Medical Sciences
- All-in-one multimodal nanotheranostic platform for image-guided therapy20 Aug 2026US 2026/0241003 A1The Johns Hopkins University
- Methods for imaging using spcct13 Aug 2026US 2026/0232805 A1
- Use of pclx-001 or pclx-002 as a radiosensitizer30 Jul 2026US 2026/0216176 A1Acylex Pharmaceuticals Inc.
Most cited
By later US patents
- Method of expanded porphyrin-oligonucleotide conjugate synthesis325US 5,565,552 ABoard of Regents, Univ. of Texas Sys. · 1996
- Texaphyrin-oligonucleotide conjugates308US 5,587,371 ABoard of Trustees, Univ. of TX Sys. · 1996
- Texaphyrin metal complexes having improved functionalization254US 5,599,923 ABoard of Regents, University of TX · 1997
- Texaphyrin compounds having improved functionalization233US 5,599,928 ABoard of Regents, The University of Texas System · 1997
- Chromophore probe for detection of nucleic acid221US 5,595,726 ABoard of Trustees, Univ. of TX Sys. · 1997